The ZUMA-2 trial demonstrated that among 60 patients with MCL, only one relapse was CD19-negative, while none of the patients who relapsed in ZUMA-5 were CD19-negative at disease progression [11]. Here, CD19 is linked to mantle cell lymphoma.